Arrowhead Pharmaceuticals, Inc. (ARWR)
61.14
-1.24
(-1.99%)
USD |
NASDAQ |
Feb 13, 09:43
Arrowhead Pharmaceuticals Cash from Investing (Quarterly) : -23.74M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 232.40M |
| Sanofi | -- |
| Ionis Pharmaceuticals, Inc. | 91.34M |
| Eli Lilly & Co. | -- |
| Cidara Therapeutics, Inc. | -176.47M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.48M |
| Cash from Financing (Quarterly) | -14.75M |
| Free Cash Flow | 327.01M |
| Free Cash Flow Per Share (Quarterly) | 0.0805 |
| Free Cash Flow to Equity (Quarterly) | 57.25M |
| Free Cash Flow to Firm (Quarterly) | 33.81M |
| Free Cash Flow Yield | 3.89% |